Jiangsu Hengrui Medicine Co., Ltd

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1970-01-01

Employees: -

Market Cap: $38.9B

Website: http://www.hrs.com.cn/english/

Clinical Trials

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Phase 3

Conditions: HER2-positive Breast Cancer

Interventions: Drug: Placebo Oral Tablet
Drug: Pyrotinib
Drug: Trastuzumab
Drug: Docetaxel

First Posted Date: 2018-07-17

Last Posted Date: 2021-08-04

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 355

Registration Number: NCT03588091

Locations: 🇨🇳
The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳
Huai'an First People's Hospital, Huaian, Jiangsu, China
🇨🇳
The Affiliated Hospital Of Qingdao University, Qingdao, Shandong, China

and more 14 locations

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Phase 2

Completed

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: SHR-1210

First Posted Date: 2018-06-15

Last Posted Date: 2024-03-15

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 156

Registration Number: NCT03558191

Locations: 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), Guangzhou, Guangdong, China

A Study to Evaluate the Safety and Efficacy of Hetrombopag Olamine in Severe Aplastic Anemia （SAA） Patient

Phase 1

Completed

Conditions: Severe Aplastic Anemia

Interventions: Drug: Hetrombopag Olamine

First Posted Date: 2018-06-14

Last Posted Date: 2022-07-29

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 55

Registration Number: NCT03557099

Locations: 🇨🇳
Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China

A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

Phase 3

Active, not recruiting

Conditions: Prostate Cancer
Hormone-Dependent Prostate Cancer

Interventions: Drug: SHR3680
Drug: Bicalutamide

First Posted Date: 2018-05-09

Last Posted Date: 2021-03-02

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 654

Registration Number: NCT03520478

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, China
🇧🇬
Complex oncological center - Bourgas, Burgas, Bulgaria
🇧🇬
MHAT - Dobrich. AD, Dobrich, Bulgaria

and more 64 locations

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Fluzoparib

First Posted Date: 2018-04-26

Last Posted Date: 2022-07-01

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 113

Registration Number: NCT03509636

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Neoplasm Malignant
Cancer, Metastatic
Tumor, Solid

Interventions: Drug: SHR9146+SHR-1210
Drug: SHR9146+SHR-1210+Apatinib

First Posted Date: 2018-04-09

Last Posted Date: 2022-11-04

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 23

Registration Number: NCT03491631

Locations: 🇨🇳
Jilin Province Cancer Hospital, Changchun, Jilin, China

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Phase 1

Completed

Conditions: Advanced Breast Cancer

Interventions: Drug: SHR6390
Drug: Letrozole or anastrozole or Fulvestrant

First Posted Date: 2018-03-29

Last Posted Date: 2023-11-21

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 104

Registration Number: NCT03481998

Locations: 🇨🇳
Ha'erbin Tumor Hospital, Ha'erbin, Heilongjiang, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
Sir Run Run Shaw Hospital of Zhejiang University, Hangzhou, Zhejiang, China

and more 1 locations

Safety and Tolerability of SHR-1316 in Subjects With Advanced Tumors

Phase 1

Conditions: Tumor

Interventions: Drug: SHR-1316

First Posted Date: 2018-03-22

Last Posted Date: 2018-03-22

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 134

Registration Number: NCT03474289

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2

Completed

Conditions: Gastric Cancer
GastroEsophageal Cancer

Interventions: Biological: SHR-1210
Drug: Capecitabine
Drug: Oxaliplatin
Drug: Apatinib

First Posted Date: 2018-03-21

Last Posted Date: 2024-01-11

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 67

Registration Number: NCT03472365

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)

Phase 2

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Drug: SHR 1210+apatinib

First Posted Date: 2018-03-13

Last Posted Date: 2023-03-21

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 190

Registration Number: NCT03463876

Locations: 🇨🇳
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy